Document:

Exhibit
10.36 

CENTURY THERAPEUTICS,
INC.

 

February 16, 2021

 

Via e-mail

 

Joseph Jimenez

122 Pepperwood Ct

Danville, CA 94506

joe.jimenez@aditumbio.com

 

Dear Joe:

 

Following our recent discussions,
I am very pleased to invite you to serve as Chairman of the Board of Directors (the “Board”) of Century Therapeutics,
Inc. (f/k/a Century Therapeutics, LLC, the “Company”), on the terms and subject to the conditions set forth below.

 

1.             Appointment.
Upon your acceptance of this letter, in connection with the conversion of the Company from a Delaware limited liability company to a
Delaware corporation (which is anticipated to occur on or before February 24, 2021) (the “Conversion”), your nomination
to serve as Chairman of the Board will be submitted to the other members of the Board for approval. In connection with your appointment,
you shall hold office until such time that your successor is duly elected and qualified, or until your earlier death, retirement, resignation
or removal from office. The terms and obligations under this letter agreement shall remain in full force and effect until your earlier
death, retirement, resignation or removal from the Board; provided that the obligations under Section 6 shall survive indefinitely.

 

2.             Duties.
As an independent director, you will be expected to attend the meetings of the Board and the Committees of the Board on which you serve,
as regularly or specially called. Board meetings are scheduled upon prior consultation with directors and are typically held in Philadelphia,
PA. You may attend and participate at each such meeting via teleconference, video conference or in person.

 

3.             Fiduciary Obligations; Governance: The Company is governed by Delaware law. The structure, practices and authority of the
Board, including matters relating to the size and composition of the Board, the election and removal of directors, requirements relating
to Board action and the appointment of executive officers, effective as of the Conversion, will be governed by the Company’s Amended
and Restated Certificate of Incorporation and Bylaws, as each may be amended from time to time (the “Organizational Documents”).

 

4.             Compensation.
As consideration for your service as a member of the Board, the Company will pay you the following compensation:

 

(a)          
Equity Award. Subject to the approval of the Board, upon the closing of an equity financing resulting in gross proceeds
to the Company of at least $155,000,000 (the “Series C Financing”), the Company will grant to you a one-time nonqualified
stock option exercisable for the purchase of 683,601 shares of the Company’s common stock, par value $0.0001

 

     

     

    

 

per share (the “Common
Stock”) (the “Option”), which, together with existing awards previously granted to you by the Company, brings
your equity ownership in the Company following the closing of the Series C Financing to 1% of the Company measured on a fully diluted
basis. The Option will: (i) be subject to the terms and conditions of the Century Therapeutics, Inc. 2018 Stock Option and Grant Plan
(as amended, restated or otherwise modified from time to time, the “Plan”) and the Non-Qualified Stock Option Agreement
by and between you and the Company (the “Award Agreement”), (ii) have an exercise price per share equal to the fair
market value per share of Common Stock on the date of the grant, as determined by the Board, and (iii) be subject to vesting requirements
such that 25% of the shares of Common Stock underlying the Option shall vest on the first anniversary of the date of grant, and thereafter,
the remaining 75% of the shares of Common Stock underlying the Option shall vest in 36 substantially equal monthly installments, in each
case if you continue to provide services to the Company as of the applicable vesting date; provided, however, that any then-unvested
portion of the Option shall automatically vest upon the closing of a Sale Event (as defined in the Plan) if you continue to provide services
to the Company through such event.

 

(b)          Annual
Retainer. Subject to approval by the Board, for so long as you continue to serve as a director of the Company, you shall be entitled
to receive an annual retainer of $50,000, payable on a quarterly basis. Such retainer shall be pro-rated for any partial year.

 

5.             Expenses. The Company will pay or reimburse the reasonable, authorized expenses incurred by you in the discharge of your
duties as a director, in accordance with the general practices and policies of the Company and upon the submission of appropriate documentation.

 

6.             Indemnification; Insurance. As a director, you will be entitled to indemnification under the Company’s Organizational
Documents and that certain Indemnification Agreement by and between the Company and you, effective as of August 19, 2019 (as the same
may be amended, restated, modified, superseded or replaced from time to time, the “Indemnification Agreement”). In
addition, the Company will also carry director and officer liability insurance and you will be a covered person under any such policy
maintained by the Company during the term of your service on the Board.

 

7.             Proprietary
Information. In your capacity as a Board member the Company will you with information of a private, secret or confidential nature
concerning the Company’s business, business relationships or financial affairs (collectively, “Proprietary Information”).
In consideration for the Company sharing with you the Company’s Proprietary Information, you agree that you will not disclose any
Proprietary Information to any person or entity other than employees or advisors of the Company or use the same for any purposes (other
than in the performance of your duties as a member of the Board) without written approval by an officer of the Company, either during
or after you serve as a member of the Board, unless and until such Proprietary Information has become public knowledge without your fault.
All such materials or copies thereof and all tangible property of the Company in your custody or possession shall be delivered to the
Company or destroyed, at the Company’s election, upon the earlier of (i) the Company’s request or (ii) termination of your
service on the Board. After such delivery or destruction, you shall not retain any such materials or copies thereof or any such tangible
property.

 

     

     

    

 

You agree that your obligations not to disclose or to use Proprietary Information and materials containing
Proprietary Information and to return materials and tangible property also extends to such types of information, materials and tangible
property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to
you or the Company.

 

8.             Obligations
to Third Parties. You represent that your service as a member of the Board does not and will not breach any agreement you have with
any current or former employer or any other person (including without limitation any nondisclosure or non-competition agreement), and
that you will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging
to any current or previous employer or others.

 

9.             Relationship
of the Parties. Nothing contained in this letter agreement shall be construed to create an employer/employee, joint venture, partnership,
or principal-agent relationship between you and the Company.

 

10.           Governing
Law; Consent to Jurisdiction. This letter agreement shall be interpreted according to and governed by the law of the State of Delaware
applicable to agreements made and performed within the State of Delaware without reference to its choice of law rules. The parties to
this Agreement hereby consent to the jurisdiction of the courts located in New Castle County, Delaware for any proceeding arising out
of or relating to this letter agreement.

 

11.           Entire
Agreement. This letter agreement and the Indemnification Agreement constitute the entire understanding between the parties with respect
to the subject matter hereof and supersedes any and all prior understandings, statements, warranties, representations and agreements,
both oral and written, relating hereto.

 

12.           Severability.
If any term of this letter agreement is held invalid, illegal, or unenforceable by a court of competent jurisdiction, that term shall
be severed and the remaining terms shall continue in full force.

 

13.           Counterparts.
This letter agreement may be executed in counterparts, including by facsimile signature, each of which shall be deemed an original but
all of which taken together shall constitute one and the same instrument.

 

[remainder of page intentionally left blank]

 

     

     

    

 

If you are in agreement with
the terms described above, please return a countersigned copy of this letter to me. We look forward to your continued participation as
a member of the Board.

 

	 	Very truly yours,	 
	 	 	 
	 	/s/ Osvaldo Flores	 
	 	 	 
	 	Osvaldo Flores, Ph.D.	 
	 	President & Chief Executive Officer
	 	 

 

ACCEPTED AND AGREED TO:

 

 

	/s/ Joseph Jimenez	 	 	Feb 16 2021	 

	Joseph Jimenez			DateExhibit 10.37

 

CENTURY THERAPEUTICS,
INC.

 

February 25, 2021

 

Via e-mail

 

Cynthia Butitta

21 Montage Way

Laguna Beach, CA

92651       

E-mail:cynthiabutitta@gmail.com

 

Dear Cynthia:

 

Following our recent discussions,
I am very pleased to invite you to serve as member of the Board of Directors (the “Board”) of Century Therapeutics,
Inc. (f/k/a Century Therapeutics, LLC, the “Company”), on the terms and subject to the conditions set forth below.

 

1.                Appointment.
Upon your acceptance of this letter, following the conversion of the Company from a Delaware limited liability company to a Delaware
corporation (which is anticipated to occur on or before February 25, 2021) (the “Conversion”), and the consummation
of an equity financing resulting in gross proceeds to the Company of at least $160,000,000 (the “Series C Financing”),
your nomination and election as an independent director will be submitted to the stockholders of the Company for approval. Following
your nomination and election, you shall hold office until such time that your successor is duly elected and qualified, or until your
earlier death, retirement, resignation or removal from office. The terms and obligations under this letter agreement shall remain in
full force and effect until your earlier death, retirement, resignation or removal from the Board; provided that the obligations under
Section 6 shall survive indefinitely.

 

2.                Duties.
As an independent director, you will be expected to attend the meetings of the Board and the Committees of the Board on which you serve,
as regularly or specially called. Board meetings are scheduled upon prior consultation with directors and are typically held in Philadelphia,
PA. You may attend and participate at each such meeting via teleconference, video conference or in person.

 

3.                Fiduciary
Obligations; Governance. The Company is governed by Delaware law. The structure, practices and authority of the Board, including
matters relating to the size and composition of the Board, the election and removal of directors, requirements relating to Board action
and the appointment of executive officers, effective as of the Conversion, will be governed by the Company’s Amended and Restated
Certificate of Incorporation and Bylaws, as each may be amended from time to time (the “Organizational Documents”).

 

4.                Compensation.
As consideration for your service as a member of the Board, the Company will pay you the following compensation:

 

(a)              Equity Award. Subject to the approval of the Board, upon the closing of the Series C Financing, the Company will grant
to you a one-time nonqualified stock option exercisable for the purchase of 375,465 shares of the Company’s common stock, par value
$0.0001

 

     

     

    

 

per share (the “Option”), which,
following the closing of the Series C Financing, is equal to 0.3% of the Company measured on a fully diluted basis. The Option will: (i)
be subject to the terms and conditions of the Century Therapeutics, Inc. 2018 Stock Option and Grant Plan (as amended, restated or otherwise
modified from time to time, the “Plan”) and the Non-Qualified Stock Option Agreement by and between you and the Company
(the “Award Agreement”), (ii) have an exercise price per share equal to the fair market value per share of Common Stock
on the date of the grant, as determined by the Board, and (iii) be subject to vesting requirements such that 25% of the shares of Common
Stock underlying the Option shall vest on the first anniversary of the date of grant, and thereafter, the remaining 75% of the shares
of Common Stock underlying the Option shall vest in 36 substantially equal monthly installments, in each case if you continue to provide
services to the Company as of the applicable vesting date; provided, however, that any then-unvested portion of the Option shall automatically
vest upon the closing of a Sale Event (as defined in the Plan) if you continue to provide services to the Company through such event.

 

(b)         Annual
Retainer. Subject to approval by the Board, for so long as you continue to serve as a director of the Company, you shall be entitled
to receive an annual retainer of $25,000, payable on a quarterly basis. Such retainer shall be pro-rated for any partial year.

 

5.                Expenses.
The Company will pay or reimburse the reasonable, authorized expenses incurred by you in the discharge of your duties as a director,
in accordance with the general practices and policies of the Company and upon the submission of appropriate documentation.

 

6.               
Indemnification; Insurance. As a director, you will be entitled to indemnification under the Company’s Organizational
Documents and an Indemnification Agreement to be entered into between the Company and you (the “Indemnification Agreement”).
In addition, the Company will also carry director and officer liability insurance and you will be a covered person under any such policy
maintained by the Company during the term of your service on the Board.

 

7.                Proprietary Information. You agree that all information, whether or not in writing, of a private, secret or confidential
nature concerning the Company’s business, business relationships or financial affairs (collectively, “Proprietary Information”)
is and shall be the exclusive property of the Company. In consideration for the Company sharing with you the Company’s Proprietary
Information, you agree (a) that you will not disclose any Proprietary Information to any person or entity other than employees or advisors
of the Company or use the same for any purposes (other than in the performance of your duties as a member of the Board) without written
approval by an officer of the Company, either during or after you serve as a member of the Board, unless and until such Proprietary Information
has become public knowledge without your fault, and (b) that any materials containing Proprietary Information which shall come into your
custody or possession shall be and are the exclusive property of the Company to be used only in the performance of your duties for the
Company. All such materials or copies thereof and all tangible property of the Company in your custody or possession shall be delivered
to the Company or destroyed, at the Company’s election, upon the earlier of (i) the Company’s request or (ii) termination
of your service on the Board. After such delivery or destruction, you shall not retain any such materials or copies thereof or any such
tangible property. You agree that your

 

     

     

    

 

obligations not to disclose or to use Proprietary Information and materials containing Proprietary
Information and to return materials and tangible property also extends to such types of information, materials and tangible property
of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to you or
the Company.

 

8.                Obligations
to Third Parties. You represent that your service as a member of the Board does not and will not breach any agreement you have with
any current or former employer or any other person (including without limitation any nondisclosure or non-competition agreement), and
that you will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging
to any current or previous employer or others.

 

9.                Relationship
of the Parties. Nothing contained in this letter agreement shall be construed to create an employer/employee, joint venture, partnership,
or principal-agent relationship between you and the Company.

 

10.             
Governing Law; Consent to Jurisdiction. This letter agreement shall be interpreted according to and governed by the law
of the State of Delaware applicable to agreements made and performed within the State of Delaware without reference to its choice of law
rules. The parties to this Agreement hereby consent to the jurisdiction of the courts located in New Castle County, Delaware for any proceeding
arising out of or relating to this letter agreement.

 

11.             
Entire Agreement. This letter agreement and the Indemnification Agreement constitute the entire understanding between the
parties with respect to the subject matter hereof and supersedes any and all prior understandings, statements, warranties, representations
and agreements, both oral and written, relating hereto.

 

12.             
Severability. If any term of this letter agreement is held invalid, illegal, or unenforceable by a court of competent jurisdiction,
that term shall be severed and the remaining terms shall continue in full force.

 

13.             
Counterparts. This letter agreement may be executed in counterparts, including by facsimile signature, each of which shall
be deemed an original but all of which taken together shall constitute one and the same instrument.

 

[remainder of page intentionally left blank]

 

     

     

    

 

If you are in agreement with
the terms described above, please return a countersigned copy of this letter to me. We look forward to your participation as a member
of the Board.

 

	 	Very truly yours,	 
	 	 	 
	 	/s/ Osvaldo Flores	 
	 	 	 
	 	Osvaldo Flores, Ph.D.
	 	President & Chief Executive Officer

 

ACCEPTED AND AGREED TO:

 

 

	/s/ Cynthia Butitta	 	 	February 25, 2021	 
	Cynthia Butitta	 	 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]